WO2011010131A1 - Compositions comprenant un oxoisoquinoléin-méthylbenzamide et un polymère - Google Patents

Compositions comprenant un oxoisoquinoléin-méthylbenzamide et un polymère Download PDF

Info

Publication number
WO2011010131A1
WO2011010131A1 PCT/GB2010/051177 GB2010051177W WO2011010131A1 WO 2011010131 A1 WO2011010131 A1 WO 2011010131A1 GB 2010051177 W GB2010051177 W GB 2010051177W WO 2011010131 A1 WO2011010131 A1 WO 2011010131A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical depot
polymer
pharmaceutical
methyl
ethyl
Prior art date
Application number
PCT/GB2010/051177
Other languages
English (en)
Inventor
Nicola Frances Bateman
Anne Elizabeth Cooper
Paul Alfred Dickinson
Philip Alexander Macfaul
Ian Alun Nash
Steven Swallow
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Publication of WO2011010131A1 publication Critical patent/WO2011010131A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine

Definitions

  • the present invention relates to a pharmaceutical depot comprising N-ethyl-3-[7- ⁇ 2-[ethyl(methyl)amino]ethoxy ⁇ -4-methyl-l-oxoisoquinolin-2(lH)-yl]-4- methylbenzamide or a pharmaceutically-acceptable salt thereof, and to uses of the pharmaceutical depot.
  • WO2006/067444 discloses quinazolinone derivatives, including N-ethyl-3-[7- ⁇ 2- [ethyl(methyl)amino] ethoxy ⁇ -4-methyl- 1 -oxoisoquinolin-2( 1 H)-yl] -4-methylbenzamide, and pharmaceutically-acceptable salts thereof, and teaches that the quinazolinone derivatives are inhibitors of the production of cytokines such as Tumour Necrosis Factor (hereinafter TNF), for example TNF ⁇ , and various members of the interleukin (hereinafter IL) family, for example IL-I, IL-6 and IL-8 (especially IL-I).
  • TNF Tumour Necrosis Factor
  • IL interleukin
  • the quinazolinone derivatives disclosed in WO2006/067444 possess pharmacological activity only by virtue of an effect on a single biological process, it is believed that the quinazolinone derivatives inhibit the effects of cytokines by virtue of inhibition of the enzyme p38 kinase.
  • p38 kinase (otherwise known as cytokine suppressive binding protein, hereinafter CSBP) and reactivating kinase (hereinafter RK) is a member of the mitogen-activated protein (hereinafter MAP) kinase family of enzymes which is known to be activated by physiological stress such as that induced by ionising radiation, cytotoxic agents, and toxins, for example endotoxins such as bacterial lipopolysaccharide, and by a variety of agents such as the cytokines, for example TNF ⁇ and IL-I. It is known that p38 kinase phosphorylates certain intracellular proteins that are involved in the cascade of enzymatic steps which leads to the biosynthesis and excretion of cytokines such as TNF ⁇ and IL-I.
  • MAP mitogen-activated protein
  • the quinazolinone derivatives disclosed in WO2006/067444 therefore are believed to be useful in the treatment of diseases or medical conditions in which excessive production of cytokines occurs, for example excessive production of TNF ⁇ or IL-I.
  • diseases and medical conditions include inflammatory and allergic diseases, such as inflammation of the joints (especially rheumatoid arthritis, osteoarthritis and gout).
  • WO2006/067444 suggests that the quinazolinone derivatives disclosed therein may be included in a pharmaceutical composition, for example in a form suitable for oral or topical use, for administration by inhalation or insufflation, or for parenteral administration, there is no disclosure in WO2006/067444 of a pharmaceutical depot comprising a quinazolinone derivative as disclosed therein, let alone of such a
  • a pharmaceutical depot comprising (i) N-ethyl-3 -[I - ⁇ 2- [ethyl(methyl)amino] ethoxy ⁇ -4-methyl- 1 -oxoisoquinolin- 2(lH)-yl]-4-methylbenzamide, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation.
  • PA pharmaceutical agent
  • N-ethyl-3 -[I - ⁇ 2- [ethyl(methyl)amino] ethoxy ⁇ -4-methyl- 1 - oxoisoquinolin-2(lH)-yl]-4-methylbenzamide is believed to be N-ethyl-3-[7-[2- [ethyl(methyl)amino]ethoxy]-4-methyl- 1 -oxo-2-isoquinolyl]-4-methyl-benzamide
  • the pharmaceutical agent (hereinafter the PA) is N-ethyl-3-[7- ⁇ 2-[ethyl(methyl)amino]ethoxy ⁇ -4-methyl- 1 - oxoisoquinolin-2(lH)-yl]-4-methylbenzamide, or a pharmaceutically-acceptable salt thereof.
  • references herein to the PA include the compound N-ethyl-3 -[7- ⁇ 2- [ethyl(methyl)amino] ethoxy ⁇ -4-methyl- 1 -oxoisoquinolin-2( 1 H)-yl] -4-methylbenzamide per se, as well as pharmaceutically-acceptable salts thereof.
  • a pharmaceutical depot is a composition that releases a PA, especially a pharmaceutically effective amount of a PA (herein N-ethyl- 3-[7- ⁇ 2-[ethyl(methyl)amino]ethoxy ⁇ -4-methyl-l-oxoisoquinolin-2(lH)-yl]-4- methylbenzamide or a pharmaceutically-acceptable salt thereof) over time, so as to provide for the controlled- and/or sustained-release administration of the PA comprised therein.
  • a PA herein N-ethyl- 3-[7- ⁇ 2-[ethyl(methyl)amino]ethoxy ⁇ -4-methyl-l-oxoisoquinolin-2(lH)-yl]-4- methylbenzamide or a pharmaceutically-acceptable salt thereof
  • N-ethyl-3 - [7- ⁇ 2- [ethyl(methyl)amino] ethoxy ⁇ -4-methyl- 1 -oxoisoquinolin-2( 1 H)- yl]-4-methylbenzamide has the structure:
  • [ethyl(methyl)amino] ethoxy ⁇ -4-methyl- 1 -oxoisoquinolin-2( 1 H)-yl] -4-methylbenzamide for including in the pharmaceutical depot of the present invention are based on reasonable medical judgement as being suitable for administration to a subject, for example a warmblooded animal such as man, without undesirable pharmacological activities and without undue toxicity.
  • Suitable pharmaceutically-acceptable salts include acid-addition salts, for example acid addition salts with an inorganic or organic acid such as hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, citric, maleic, tartaric, fumaric, hemifumaric, succinic, hemisuccinic, mandelic, methanesulfonic, dimethanesulfonic, ethane- 1 ,2-sulfonic, benzenesulfonic, salicylic or 4-toluenesulfonic acid.
  • an inorganic or organic acid such as hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, citric, maleic, tartaric, fumaric, hemifumaric, succinic, hemisuccinic, mandelic, methanesulfonic, dimethanesulfonic, ethane- 1 ,2-sulfonic, benzene
  • 2(lH)-yl]-4-methylbenzamide and pharmaceutically-acceptable salts thereof may be synthesised from suitable starting materials using standard procedures of organic chemistry, for example as discussed in WO-A-2005/042502.
  • the pharmaceutical depot of the present invention enables the administration of the PA using a controlled- and/or sustained-release formulation so as to maintain a therapeutic level of the PA over an extended period of time. This is advantageous because it reduces the frequency of dosing and provides a convenient mode of administration of the PA, which is particularly desirable for the administration of the PA directly into the joint, i.e. by intra-articular administration. Controlled- and/or sustained-release formulations also can reduce the severity and frequency of any undesirable side effects associated with a particular PA. Improvements in the convenience of administration and reduced occurrence and severity of side effects in turn enhance patient compliance.
  • PA included in the pharmaceutical depot of the present invention is hydro lyrically stable in the acidic microclimate created upon the degradation of the polymer included therein and therefore that the PA is suitable for including in the pharmaceutical depot.
  • the PA was identified as being suitable for including in a pharmaceutical depot according to a method disclosed in a co-pending patent application filed by AstraZeneca AB on the same day as the present application. The method comprises the step of performing a screening cascade on the PA, wherein the screening cascade includes the step(s) of conducting a low concentration hydrolytic stress test on the PA and/or conducting a high concentration hydrolytic stability assay on the PA.
  • the present inventors have surprisingly found that the PA included in the pharmaceutical depot of the present invention can be provided at a sustained high local concentration of the PA at a site of administration, for example at a joint, to provide for the effective controlled- and/or sustained-release of the PA.
  • the PA included in the pharmaceutical depot of the present invention can be provided at a sustained high local concentration of the PA at a site of administration, for example at a joint, to provide for the effective controlled- and/or sustained-release of the PA.
  • pharmaceutical depot is effective to slowly release the PA so as to achieve a long acting effect.
  • the PA may be included in the pharmaceutical depot of the present invention without any chemical modification being required prior to its inclusion therein.
  • a “pharmaceutical agent” is an agent that causes a pharmacological effect in a subject to which it is administered, for example in a warm-blooded animal such as man, for example so as to treat or prevent a disease or medical condition.
  • the PA in the pharmaceutical depot of the present invention is N-ethyl-3-[7- ⁇ 2-[ethyl(methyl)amino]ethoxy ⁇ -4-methyl-l- oxoisoquinolin-2(lH)-yl]-4-methylbenzamide, or a pharmaceutically-acceptable salt thereof, which is believed to cause a pharmacological effect by means of the inhibition of the effects of cytokines (such as TNF, for example TNF ⁇ , and various members of the IL family, for example IL-I, IL-6 and IL-8) by virtue of inhibition of the enzyme p38 kinase.
  • cytokines such as TNF, for example TNF ⁇
  • various members of the IL family for example IL-I, IL-6 and IL-8
  • the PA that is included in the pharmaceutical depot of the present invention is effective in the treatment of an inflammatory disease or condition, for example a condition caused by inflammation of a joint, such as osteoarthritis in which both acute and chronic synovial inflammation may occur.
  • an inflammatory disease or condition for example a condition caused by inflammation of a joint, such as osteoarthritis in which both acute and chronic synovial inflammation may occur.
  • Osteoarthritis also known as degenerative arthritis or degenerative joint disease
  • improved formulations for delivery of PAs for treatment of osteoarthritis are highly desirable.
  • the PA is present in the pharmaceutical depot of the present invention in a therapeutically effective amount.
  • a “therapeutically effective amount” is any amount of the PA (for example as contained in the pharmaceutical depot) which, when administered to a subject suffering from a disease or medical condition against which the PA is effective, causes reduction, remission, or regression of the disease or medical condition.
  • the pharmaceutical depot will necessarily vary depending upon the nature and severity of the disorder to be treated and the particular patient treated, according to well known principles of medicine. Additionally, the therapeutically effective amount of the PA that is included in the pharmaceutical depot will necessarily vary according to the desired controlled- and/or sustained-release profile, for example depending on the period of time over which release of the PA is required and the concentration of PA desired over that time.
  • the pharmaceutical depot of the present invention comprises a polymer which degrades to create an acidic microclimate, for example a polymer which degrades in the presence of water to create an acidic microclimate.
  • the acidic pH is essentially uniform in the localised area and differs from the surrounding area, which may be at a physiological pH (typically of about pH 7.4).
  • the acidic pH is typically a pH of less than about 7.4, for example a pH in the range of from about 1 to about 7, such as from about 3 to about 7; conveniently from about 1 to less than 7 or from about 3 to less than 7.
  • the PA is dispersed or encapsulated in the polymer, such that the PA is continually released from the polymer as the polymer degrades over time to create the acidic microclimate.
  • the PA that is included in the pharmaceutical depot of the present invention has been found to be hydrolytically stable in the acidic microclimate that is created by the degradation of the polymer.
  • the release of the PA from the polymer provides for the controlled- and/or sustained-release of the PA from the pharmaceutical depot into a subject, for example a warm-blooded animal such as man, to which the pharmaceutical depot is administered.
  • a high local concentration i.e.
  • the pharmaceutical depot delivers the PA to the subject at concentrations effective for treatment of the particular disease or medical condition over a sustained period of time.
  • any suitable polymer may be used in the pharmaceutical depot of the present invention, provided that the polymer degrades to create an acidic microclimate, i.e. upon administration to a subject, for example to a warm-blooded animal such as man, and is biodegradable and biocompatible.
  • biocompatible we mean a material that is compatible with living tissue or a living system by not being toxic, injurious, or physiologically reactive and not causing immunological rejection.
  • biodegradable we mean a material that is degraded in a biological environment.
  • a polymer may be "biodegradable” such that the entire polymer biodegrades and does not need to be removed after use, i.e. once all of the PA has been released.
  • Such polymers may comprise hydrolysable and enzymatically cleavable ester linkages that break down under biological conditions (for example in the presence of water and biological enzymes found in tissues of warm-blooded animals such as humans) to produce non-toxic, biocompatible and/or biodegradable products.
  • a polymer may be "biodegradable” by virtue of having a finite half-life in a biological environment. For example the polymer may have a half- life of from 1 to 12 months, such as from 1 to 6 months.
  • the polymer includes at least one acidic functional group or at least one functional group that may react to produce an acidic functional group, i.e. which acidic functional group is a group that is capable of donating a proton to a basic functional group such as an amine.
  • suitable acidic functional groups include carboxylic acid groups (i.e. -CO 2 H) and sulfonic acid groups (i.e. -S(O) 2 OH).
  • suitable functional groups that may react to produce an acidic functional group include esters (i.e. RC(O)OR, where R may represent alkyl or aryl), which esters may react with water to produce a corresponding carboxylic acid group and an alcohol.
  • the polymer is selected so as to degrade and release the PA over a period of from about 30 to 90 days.
  • the polymer may degrade and release the PA over a period of about 30, about 60 or about 90 days.
  • the polymer may degrade and release the PA over a period of about 120, about 150 or about 180 days.
  • Suitable polymers include a polyester of a hydroxyfatty acid and derivatives thereof
  • the polymers are copolymers they may be any of random, block and graft copolymers.
  • any one of D-isomers, L-isomers and DL-isomers may be used.
  • ⁇ -hydroxycarboxylic acid polymer preferably lactic acid-glycolic acid polymer
  • its ester preferably lactic acid-glycolic acid polymer
  • poly- ⁇ -cyanoacrylic acid esters etc.
  • lactic acid-glycolic acid copolymer also referred to as poly(lactide-co-glycolide) or poly(lactic-co-glycolic acid), and hereinafter referred to as PLGA
  • PLGA lactic acid-glycolic acid copolymer
  • the term PLGA includes polymers of lactic acid (also referred to as polylactide, poly(lactic acid), or PLA).
  • Suitable PLGA polymers may have a molar ratio of lactic acid:glycolic acid in the range of 100:0 to 50:50, conveniently in the range of 95:5 to 50:50.
  • the PLGA polymer may have a molar ratio of lactic acid:glycolic acid of 95:5 or of 50:50.
  • Suitable PLGA polymers may have a block length in the range of from 1 to 5, preferably of from 2 to 4.
  • Suitable PLGA polymers may have a weight-average molecular weight of from about 3,000 to about 50,000, preferably of about 4,000 to about 40,000, and more preferably of about 5,000 to about 30,000 Daltons.
  • the degree of dispersion (weight- average molecular weight/number-average molecular weight, hereinafter referred to as polydispersity) may range from about 1.2 to about 4.0, preferably from about 1.3 to about 3.5.
  • the weight-average molecular weight, number-average molecular weight and polydispersity may be determined by any suitable method or means, for example by size exclusion chromatography (SEC) with narrow polydispersity polystyrene reference substances with peak molecular weights of 1 ,000,000, 130,000, 50,000, 20,000, 10,000, 5,000, 2,000, and 580 respectively.
  • SEC size exclusion chromatography
  • the determination may be carried out using a SEC column Mixed Bed D 5 ⁇ m (manufactured by Polymer Laboratories Ltd., UK) and using 5% methanol in tetrahydrofuran as the mobile phase.
  • the PLGA may be prepared by any conventional method, or may be commercially available.
  • PLGA can be produced by ring-opening polymerisation with a suitable catalyst from cyclic lactide, glycolide, etc. (see Encyclopedic Handbook of Biomaterials and Bioengineering Part A: Materials, Volume 2, Marcel Dekker, Inc. (1995); EP-0058481B2; Effects of polymerization variables on PLGA properties: molecular weight, composition and chain structure and Dorta et al, Int. J. Pharm., 100, pp 9-14 (1993)).
  • PLGA is biodegradable by means of the degradation of the entire solid polymer composition, due to the break down of hydro lysable and enzymatically cleavable ester linkages under biological conditions (for example in the presence of water and biological enzymes found in tissues of warm-blooded animals such as humans) to form lactic acid and glycolic acid.
  • Both lactic acid and glycolic acid are water-soluble, nontoxic products of normal metabolism, which may further biodegrade to form carbon dioxide and water.
  • PLGA is believed to degrade by means of hydrolysis of its ester groups in the presence of water, for example in the body of a warm-blooded animal such as man, to produce lactic acid and glycolic acid and create the acidic microclimate. Lactic and glycolic acid are by-products of various metabolic pathways in the body of a warm- blooded animal such as man under normal physiological conditions and therefore are well tolerated and produce minimal systemic toxicity.
  • the polymer is provided in any suitable form in which the PA may be dispersed or encapsulated therein prior to the degradation of the polymer.
  • the PA may be dispersed or encapsulated therein prior to the degradation of the polymer.
  • pharmaceutical depot may comprise the polymer in the form of microparticles or nanoparticles, or in a liquid form, with the PA dispersed or encapsulated therein.
  • Suitable microparticles typically have an average particle size in the range of 0.1 to lOOO ⁇ m, preferably 1 to 750 ⁇ m and more preferably 10 to 500 ⁇ m.
  • Suitable nanoparticles typically have an average particle size in the range of 1 to 2000nm, preferably 10 to lOOOnm, and more preferably 50 to 500nm.
  • microparticles are substantially spherical in shape (i.e. are microspheres).
  • the microparticles may be prepared using any appropriate method, such as by a solvent evaporation or solvent extraction method.
  • a suitable volatile organic solvent for example a ketone such as acetone, a halogenated hydrocarbon such as chloroform or methylene chloride, a halogenated aromatic hydrocarbon, a cyclic ether such as dioxane, an ester such as ethyl acetate, a nitrile such as acetonitrile, or an alcohol such as ethanol
  • a suitable emulsion stabiliser for example polyvinyl alcohol, PVA.
  • the organic solvent is then evaporated to provide microparticles with the PA encapsulated therein.
  • the PA and polymer may be dissolved in a polar solvent (such as acetonitrile, dichloromethane, methanol, ethyl acetate or methyl formate) and then dispersed in an aqueous phase (such as a water/PVA solution).
  • a polar solvent such as acetonitrile, dichloromethane, methanol, ethyl acetate or methyl formate
  • an aqueous phase such as a water/PVA solution
  • the pharmaceutical depot may comprise the polymer (such as PLGA as described above) in the form of microparticles with the PA encapsulated therein.
  • the pharmaceutical depot may comprise a PLGA polymer having a
  • Such a pharmaceutical depot may be suitable for controlled- and/or sustained-release of the PA over a period of about 30 days.
  • the pharmaceutical depot may comprise a PLGA polymer having a lactide:glycolide molar ratio of 95:5 in the form of microparticles with the PA encapsulated therein.
  • Such a pharmaceutical depot may be suitable for controlled- and/or sustained-release of the PA over a period of from about 60 to 90 days.
  • Such a pharmaceutical depot may be suitable for controlled- and/or sustained-release of the PA over a period of up to 120, up to 150 or up to 180 days.
  • the pharmaceutical depot may comprise the PA and the polymer in any suitable amounts.
  • the pharmaceutical depot may comprise from 1 to 30% by weight of the PA and from 70 to 99% by weight of the polymer.
  • the PLGA when the pharmaceutical depot of the present invention comprises PLGA microparticles, the PLGA may be present in an amount ranging from about 70% to about 99% by weight of the microparticles. This amount of PLGA may be used when about 1% to about 30% by weight of the PA is loaded into the microparticles. Also, this amount of the polymer is calculated for the microparticles comprising the PA and the PLGA, but not other pharmaceutical excipients, for example used for suspending the microparticles before lyophilisation. The PLGA may be used in an amount of from about 88% to about 90% by weight of the microparticles, when about 10% to about 12% by weight of the PA is loaded in the microparticles. The proportion of the polymer typically depends on the strength of pharmacological activity of the PA used and the rate and duration of release of the PA.
  • the pharmaceutical depot may further comprise a suitable pharmaceutically- acceptable diluent or carrier, which should be water miscible.
  • suitable diluents or carriers include, for example, suitable porosity-modifying agents (such as sodium chloride) that rapidly dissolve leaving pores and/or suitable plasticisers to modify the rate of diffusion and/or reduce porosity (see, for example, Burgess, D. J., Hickey, A. J., Drugs and the Pharmaceutical Sciences (149) pp 305-353).
  • the diluent or carrier may be included in the pharmaceutical depot in any suitable amount.
  • the diluent or carrier may be included in an amount of from 0 to 50% by weight of the total composition.
  • the pharmaceutical depot does not contain an additional diluent or carrier.
  • the pharmaceutical depot typically is provided for local delivery at a desired site of treatment, such as at a joint.
  • the pharmaceutical depot may be formulated for administration by injection, such as by intra-articular injection.
  • the pharmaceutical depot may be provided in an injectable form (i.e. as an injectable pharmaceutical depot).
  • injectable we mean that the pharmaceutical depot can be drawn into a syringe and injected into a subject, for example a warm-blooded animal such as man, without causing adverse effects due to the presence of solid material in the depot.
  • the pharmaceutical depot may be injectable into a joint, such as an inflamed joint.
  • Suitable joints include knee, hip, shoulder, ankle, elbow, wrist, toe, finger and spinal facet joints.
  • the pharmaceutical depot remains in the joint after injection thereto and achieves a local delivery of the PA in a controlled and sustained manner, preferably over a period of time ranging from 30 to 90 days.
  • Pharmaceutical depots that achieve a local delivery of the PA in a controlled and sustained manner over a period of up to 90 days are advantageous because this minimises the number of local injections required to be made to a joint, which enables the depots to meet current recommendations for intra-articular therapy which advise not to exceed three to four small (about 2 ml) local injections into a joint per year due to possible adverse effects.
  • the pharmaceutical depot may be formulated for injection into the intra-articular space of an affected joint, for example into the synovial fluid-containing portion of an affected joint, such as at an osteoarthritis site.
  • the synovial fluid is contained within a central joint space defined by opposing bones of the joints. The present inventors have found that upon injection of the pharmaceutical depot into the synovial fluid, the PA is released and substantially enters the surrounding tissue with only minor amounts entering the blood stream, i.e. to achieve a high local
  • the pharmaceutical depot provides an acceptable "burst" (i.e. release of PA) on the first day following administration, which is advantageous in use and is unexpected in view of the teaching of the prior art, such as in US-6,217,911, which teaches that little or no burst release is preferred.
  • the efficient release profile provided by the pharmaceutical depot of the present invention would not have been predicted from the prior art and aids in the effectiveness of the pharmaceutical depot.
  • the pharmaceutical depot provides a sustained high local concentration of the PA in an articular joint upon administration by injection thereto, such as above 100 nanomolar.
  • Injectable pharmaceutical depots may comprise a suspension or dispersion of the
  • Suitable diluents or carriers include aqueous diluents or carriers such as an isotonic aqueous solution of a viscosity improver (such as sodium
  • injectable pharmaceutical depots may comprise further active agents, such as a local anaesthetic.
  • the pharmaceutical depot of the present invention may be formulated for human medicine or veterinary use.
  • a pharmaceutical depot formulated for intra-articular injection for human medicine or veterinary use may be provided.
  • the present invention further provides a pharmaceutical depot as defined herein for use in inhibiting the effects of cytokines, for example by virtue of the inhibition of the enzyme p38 kinase, in a subject.
  • a pharmaceutical depot as defined herein for inhibiting the effects of cytokines, for example by virtue of the inhibition of the enzyme p38 kinase, in a subject.
  • a pharmaceutical depot as defined herein in the manufacture of a medicament for use in inhibiting the effects of cytokines, for example by virtue of the inhibition of the enzyme p38 kinase, in a subject.
  • a method for inhibiting the effects of cytokines for example by virtue of the inhibition of the enzyme p38 kinase, in a subject in need thereof, which method comprises administering to said subject a pharmaceutical depot as defined herein.
  • the present invention further provides a pharmaceutical depot as defined herein for use in the prevention or treatment of an inflammatory disease, such as osteoarthritis, in a subject.
  • an inflammatory disease such as osteoarthritis
  • a pharmaceutical depot as defined herein for the prevention or treatment of an inflammatory disease, such as osteoarthritis, in a subject.
  • a pharmaceutical depot as defined herein in the manufacture of a medicament for use in the prevention or treatment of an inflammatory disease, such as osteoarthritis, in a subject.
  • a method for the prevention or treatment of an inflammatory disease such as osteoarthritis, in a subject in need thereof, which method comprises administering to said subject a pharmaceutical depot as defined herein.
  • the "subject" to which the pharmaceutical depot of the invention is to be administered is an animal, especially a warm-blooded animal, such as a domestic animal or man, particularly man.
  • a pharmaceutical depot was prepared that comprised PLGA microparticles encapsulating N-ethyl-3-[7- ⁇ 2-[ethyl(methyl)amino]ethoxy ⁇ -4-methyl-l-oxoisoquinolin-2(lH)-yl]-4- methylbenzamide as the PA.
  • the resulting emulsion was added to water (1250 ml) at 30 0 C and stirred at 500rpm (using a Heidolph RZRl stirrer) for 1 hour.
  • the resulting suspension was cooled in an ice bath and the microparticles allowed to sediment for 45 minutes. Approximately 90% (by volume) of the supernatant was removed, taking care not to disturb the sedimented microparticles.
  • Water (1 L) was added and the process repeated. Approximately 95% (by volume) of the supernatant was removed and the microparticles transferred to a glass test tube.
  • the wash/sedimentation cycle was repeated a further 2 times and the microparticles were transferred to a freeze dry vial with the minimum volume of water.
  • the vial was flash frozen and the microparticles were freeze- dried for 48 hours,
  • microparticles with 50:50 PLGA provided reasonable encapsulation efficiencies, producing N-ethyl-3 -[7- ⁇ 2-[ethyl(methyl)amino]ethoxy ⁇ -4-methyl- 1 -oxoisoquinolin- 2(lH)-yl]-4-methylbenzamide loads of about 7%.
  • the in vitro release profile data is shown in Figure 1.

Abstract

La présente invention concerne un produit pharmaceutique à effet retard comprenant (i) du N-éthyl-3-[7-{2-[éthyl(méthyl)amino]éthoxy}-4-méthyl-1-oxoisoquinoléin-2(1H)-yl]-4-méthylbenzamide, ou un sel pharmaceutiquement acceptable de ce composé, en tant qu'agent pharmaceutique (PA) et (ii) un polymère qui se dégrade pour créer un micro-environnement acide, le PA étant libéré du polymère lors de la dégradation de ce polymère.
PCT/GB2010/051177 2009-07-21 2010-07-20 Compositions comprenant un oxoisoquinoléin-méthylbenzamide et un polymère WO2011010131A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22716709P 2009-07-21 2009-07-21
US61/227,167 2009-07-21

Publications (1)

Publication Number Publication Date
WO2011010131A1 true WO2011010131A1 (fr) 2011-01-27

Family

ID=42968514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/051177 WO2011010131A1 (fr) 2009-07-21 2010-07-20 Compositions comprenant un oxoisoquinoléin-méthylbenzamide et un polymère

Country Status (1)

Country Link
WO (1) WO2011010131A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
EP0058481B2 (fr) 1981-02-16 2003-05-21 AstraZeneca AB Compositions pharmaceutiques pour la libération continue de la substance active
WO2004024694A1 (fr) * 2002-09-10 2004-03-25 Kyorin Pharmaceutical Co., Ltd. Derive de 4-(aryle substitue)-5-hydroxyisoquinolinone
WO2005042502A1 (fr) 2003-10-24 2005-05-12 Astrazeneca Ab Derives d'amides
WO2006067444A1 (fr) 2004-12-24 2006-06-29 Astrazeneca Ab Dérivés d'amide
WO2007149031A1 (fr) * 2006-06-19 2007-12-27 Astrazeneca Ab Dérivés d'isoquinoléine et leur application en tant qu'inhibiteurs de maladies faisant intervenir les cytokines

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058481B2 (fr) 1981-02-16 2003-05-21 AstraZeneca AB Compositions pharmaceutiques pour la libération continue de la substance active
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
WO2004024694A1 (fr) * 2002-09-10 2004-03-25 Kyorin Pharmaceutical Co., Ltd. Derive de 4-(aryle substitue)-5-hydroxyisoquinolinone
WO2005042502A1 (fr) 2003-10-24 2005-05-12 Astrazeneca Ab Derives d'amides
WO2006067444A1 (fr) 2004-12-24 2006-06-29 Astrazeneca Ab Dérivés d'amide
WO2007149031A1 (fr) * 2006-06-19 2007-12-27 Astrazeneca Ab Dérivés d'isoquinoléine et leur application en tant qu'inhibiteurs de maladies faisant intervenir les cytokines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Encyclopedic Handbook of Biomaterials and Bioengineering Part A: Materials", vol. 2, 1995, MARCEL DEKKER, INC.
BURGESS, D. J.; HICKEY, A. J., DRUGS AND THE PHARMACEUTICAL SCIENCES, vol. 149, pages 305 - 353
DORTA ET AL., INT. J. PHARM., vol. 100, 1993, pages 9 - 14

Similar Documents

Publication Publication Date Title
Heller et al. Poly (ortho esters)–their development and some recent applications
JP5053846B2 (ja) 生物活性化合物の制御放出送達用医薬組成物
TWI377958B (en) In-situ gelling drug delivery system
US20210212934A1 (en) Methods for providing long-lasting anesthetic effect using microparticles
JPH07309897A (ja) オクトレオチド−パモン酸塩及びその製造方法
KR20040018407A (ko) 방출 프로필을 개선하기 위하여 생분해성 물질내에미소입자를 포함하는 생활성제 수송 시스템
US20170135996A1 (en) Pharmaceutical depot for n-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide
JP2016527308A (ja) エンテカビル微小球及びこれを含む非経口投与用医薬組成物
WO2011010131A1 (fr) Compositions comprenant un oxoisoquinoléin-méthylbenzamide et un polymère
US20140045895A1 (en) Pharmaceutical depot for 5-fluoro-2-[[(1s)-1-(5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile
WO2011010132A1 (fr) Composé 600
CN110090293B (zh) 一种抑制plga微球中多肽类药物酰化副反应的方法
CN117715625A (zh) 用于治疗晶体和非晶体相关急性炎症性关节炎的包含秋水仙碱的关节内注射用剂型
CN1754535B (zh) 紫杉醇类物质的局部注射用缓释微球、其制备方法及应用
KR20030005997A (ko) 뇌종양 치료용 국소이식형 서방성 항암제제

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10752115

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10752115

Country of ref document: EP

Kind code of ref document: A1